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X-ray crystallography is now a recognized technique for ligand
screening, especially for fragment-based drug design. How-
ever, protein crystal handling is still tedious and limits further
automation. An alternative method for the solution of crystal
structures of proteins in complex with small ligands is
proposed. Crystallization drops are directly exposed to an
X-ray beam after cocrystallization or soaking with the desired
ligands. The use of dedicated plates in connection with an
optimal parametrization of the G-rob robot allows efficient
data collection. Three proteins currently under study in our
laboratory for ligand screening by X-ray crystallography were
used as validation test cases. The protein crystals belonged
to different space groups, including a challenging monoclinic
case. The resulting diffraction data can lead to clear ligand
recognition, including indication of alternating conformations.
These results demonstrate a possible method for automation
of ligand screening by X-ray crystallography.
Received 18 April 2011





X-ray crystallography is now the most classical method of
obtaining structural information on biological macromolecules.
By mid-2010, 46 872 biological macromolecule structures had
been deposited in the Protein Data Bank (PDB; www.rcsb.org/
pdb; Rose et al., 2011), with most of them being obtained
by X-ray crystallography. The importance of X-ray crystallo-
graphy in the field of rational drug design is now well estab-
lished. It includes determination of the mode of binding of
known ligands for hit-to-lead optimization and also the iden-
tification of weak ligands through fragment screening (Murray
& Blundell, 2010; Schulz & Hubbard, 2009; Chessari &
Woodhead, 2009).
Although widely used, this technique includes several
difficult steps. It requires the production of significant amounts
of pure and stable material (protein, nucleic acid etc.), crys-
tallization, harvesting, cryocooling, data collection on
laboratory or synchrotron X-ray sources and data processing
to build a model of the structure.
Significant improvements have been made to X-ray sources
and data processing is now highly automated (Joachimiak,
2009; Cymborowski et al., 2010). Automated crystallization
assays are performed using dedicated robots and pre-
established conditions. Nanodispensers have significantly
improved the throughput of crystallogenesis by decreasing the
amount of material required.
However, the detection and handling of crystals to be used
for data collection remains an important bottleneck. A
previous breakthrough in the selection of good-quality crystals
has been described. As an alternative to visualization of
crystallization drops, the scanning of crystallization plates with
an X-ray beam has been developed (Jacquamet et al., 2004). Its
advantages are threefold: (i) it provides direct access to rele-
vant information (diffraction, crystal quality and nature and,
in many cases, unit-cell parameters, space group etc.), (ii) the
method can be fully automated with a high reliability com-
pared with the shape-recognition software used in the classical
automated visualization setup and (iii) this analysis can be
carried out without any manipulation of individual crystals,
thus preserving the crystal integrity, in contrast to the classical
procedure which includes physical manipulation of individual
crystals, soaking in cryoprotectants and cryocooling, which are
all steps that could potentially damage the crystal. Never-
theless, these crystallization plates and their handling limited
the possibility of collecting sufficient diffraction data,
preventing routine use in structure determination.
In parallel, the rapid development of ligand screening by
X-ray crystallography has led to an urgent need for efficient
and possibly fully automated methods for cocrystallization
or soaking and subsequent structure determination with little
crystal handling.
Firstly, new plates with improved geometry and polymers
were designed. Meanwhile, the G-Rob robot (developed
on beamline FIP-BM30A at the ESRF and commercialized by
NatX-ray, Grenoble, France) was adapted to collect diffrac-
tion data at various tilting angles (initially 25 to +25 and
then 40 to +40). A similar development at SLS beamline
X06DA now enables in situ X-ray diffraction screening to
allow the rapid selection of crystals suitable for structure
determination (Bingel-Erlenmeyer et al., 2011). Our aim was
first to check the possible detection of a ligand bound to a
protein. The examples described here demonstrate different
cases of cocrystallization or soaking with a ligand as well as the
use of low- and high-symmetry protein crystals. The quality of
the data was sufficient to analyze in detail the mode of
binding, the geometry of the active site and local structural
rearrangements.
These results indicate that this methodology can be widely
used for ligand screening by X-ray crystallography.
2. Materials and methods
2.1. A new low-profile plate
A new plate was designed to limit absorption by the matter
surrounding the crystal drop (CrystalQuick X from Greiner
Bio-One, Germany), as shown in Fig. 1. This was achieved by
reducing the thickness of the well bottom to 300 mm and by the
choice of an adapted material: the Cyclic Olefin Copolymer, a
polyolefin with low birefringence properties. This resulted in a
significantly reduced scattering profile (Bingel-Erlenmeyer et
al., 2011). Similarly, the profile of the reservoir and the drop
location were optimized to permit the use of a large angle
range, making it possible to collect up to an 80 total range at
3.45 A˚ resolution on a synchrotron beamline at 0.9 A˚ wave-
length, 2.7 A˚ resolution using a molybdenum source or 5.9 A˚
resolution using a copper source, allowing the collection of a
complete data set in many cases.
Initial attempts were made with the lower and upper limits
set to 25 and +25, respectively. This implied the collection
of three incomplete data sets in the case of the monoclinic
crystals of Erk-2 (see below) to obtain an 83% complete data
set. Further improvements in the available angles (40 to
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Figure 1
(a) View of the new 96-well CrystalQuick X plates (Greiner Bio-One) used for crystallogenesis and in situ diffraction. (b) Detailed view of the geometry
of the plate well. (c) View of the plate hold by the CATS/G-Rob system in the X-ray beam during data collection.
+40) for plate inclination led to almost complete data sets
using only one crystal even in the case of the monoclinic space
group. In all the test cases the crystals did not suffer signifi-
cantly from their exposure to the X-ray beam.
2.2. In-plate cocrystallization or soaking
Crystallization drops were prepared with a Cartesian
HoneyBee X8 crystallization robot (Genomic Solutions Inc.)
equipped with eight independent needles and a liquid-
detection system. For crystallization, 96-well CrystalQuick
X plates (Greiner Bio-One) with square drop locations were
used. The wells were filled with 70 ml crystallization buffer,
and 250 nl of the reservoir was mixed with 250 nl of the
protein sample prior to deposition on the drop location. The
large volume of the protein drop allowed the subsequent
addition of a ligand solubilized in 100% DMSO (50 nl) while
maintaining the final concentration in solvent as low as
possible (10% in our test cases). The plate was then sealed
with a transparent plastic film (Greiner G-676070) and kept at
291 K until beam time became available.
2.3. Protein samples
For the tests, we used well behaved proteins that had
previously been studied in our laboratory. They crystallized
readily and diffracted well. Furthermore, we took advantage
of their different space groups (monoclinic, orthorhombic and
tetragonal) to evaluate the limit of the currently available
range of orientation angles for the plates.
The crystallization of the protein kinase Erk-2 from rat has
been described previously (Zhang et al., 1994) and was only
slightly modified. The precipitant solution now contained
2 mM MgSO4 in addition to the previously used precipitant.
The reproducibility of crystal growth was further improved by
using microseeding beeds (Hampton Research, USA). Up to
15 high-quality crystals could be grown in a 96-well plate
within a few days. Within two weeks, data were collected using
the G-rob plate handler and the X-ray beam at beamline FIP-
BM30A (ESRF). The first attempts were made with an
adenine derivative, 2-amino-6-(3-bromophenyl)purine. This
chemical compound corresponds to a fragment and was
synthesized following a classical chemical route (data not
shown). The second compound used was an adenosine deri-
vative bearing a Br atom at its C8 position and a derivatization
at its 50 position. In both cases, the crystal shapes and lattice
were little affected by ligand addition.
The crystallization of the complex between human RXR
ligand-binding domain and an organotin (tributyltin; TBT) in
the presence of a co-activator peptide (Tif2) has previously
been reported (le Maire et al., 2009). Crystallization of this
ternary complex was reproduced in the new plate and large
crystals appeared within a few days.
The crystallization of a variant of human cyclophilin CypD
bearing a K133I mutation has previously been described
(Schlatter et al., 2005) and could be reproduced in the new
plate with little modification. The reproducibility of crystal
growth was further improved using microseeding beeds
(Hampton Research, USA). However, this remained a
limiting factor, with only a handful of high-quality crystals
being grown within a few days.
2.4. Data collection
Data were collected on the FIP-BM30A beamline at the
ESRF (Grenoble, France) equipped with an ADSC Q315r
CCD detector. Centring was manually performed for each
crystal using solely the focus at zero tilting as a quality esti-
mate. The diffraction quality was then tested at various angles.
Residual off-centring, after taking into account refraction
across the plastic, was corrected in a trial-and-error manner.
2.5. Data processing
Data processing was performed using MOSFLM (Leslie,
2006) and SCALA from the CCP4 suite (Winn et al., 2011).
Molecular replacement was performed using MOLREP
(Vagin & Teplyakov, 2010). Structure refinement was
performed in parallel using REFMAC5 (Murshudov et al.,
2011) or PHENIX (Adams et al., 2010). In the case of the high-
resolution structure of CypD, manual model building was
performed using Coot (Emsley & Cowtan, 2004).
3. Results
3.1. Crystal structure of Erk-2 in complex with 6PB
As a first test, we soaked a crystal of protein kinase Erk-2
with a brominated arylpurine derivative. This compound,
referred to in the following as 6PB, corresponds to a privileged
pharmacophore for protein kinases bearing a brominated
phenyl group. This compound was known to bind from a
previous experiment using cryocooled crystals (see below).
The crystals of Erk-2 diffracted well, but their low symmetry
represented a challenge for the collection of a complete data
set owing to the geometric limit in plate handling.
X-ray data were collected from four distinct crystals from
four different crystallization drops. The best three data sets
were merged to obtain an 83% complete data set at 2.14 A˚
resolution. The structure was solved straightforwardly using
isomorphous replacement. The electron density assigned to
the ligand was clearly visible at all steps although the ligand
had been omitted (data not shown). In parallel, to limit any
potential bias, multiple molecular replacements were
performed usingMOLREP (Vagin & Teplyakov, 2010) and all
available structures of Erk-2 (and some potentially closely
related protein kinases) using the @TOME-2 server (Pons &
Labesse, 2009). The results are available at http://
atome.cbs.cnrs.fr/AT2/EG/47415/atome.html. The best solu-
tion appeared to be that obtained using PDB entry 1gol
(Robinson et al., 1996) according to the R factor 30.2%),
although the contrast appeared to be better (21.1 versus 16.6)
for the third best solution (PDB entry 4erk, with an R factor of
34.7%; Wang et al., 1998). After ten steps of rigid-body
refinement using REFMAC5 (Murshudov et al., 1997), the R
factor was as low as 27.2% (Rfree = 27.6%). The electron
density already revealed some variations in side-chain
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orientations as well as more pronounced but local
rearrangements in some loops. In addition, extra electron
density was clearly visible in the ATP-binding site. Ten steps of
restrained refinement using REFMAC5 confirmed the first
conclusion and lowered the R factor to 24.7 (Rfree = 28.2%).
Ten steps of TLS refinement (Winn et al., 2001) followed by
final minimization (ten steps of restrained refinement) in
REFMAC5 led to very clear electron density despite the lack
of a manual rebuilding step (R factor and Rfree of 23.6% and
28.1%, respectively). The 2-aminopurine bearing a bromo-
benzyl group was clearly recognized (Fig. 2b). It appears in the
same position as that observed in an equivalent but cryo-
cooled sample obtained classically (Fig. 2c). The ligand was
added using the ‘FindLigand’ function in Coot and a new
round of restrained refinement was performed using
REFMAC5. The final parameters of this partial refinement are
given in Table 1 together with those for the classical refine-
ment performed on the cryocooled crystal.
Alternatively, a fully automatic refinement was performed
using the PHENIX suite (Adams et al., 2010). We started from
the same molecular refinement solution (PDB entry 1gol) as
above. Firstly, a rigid-body refinement with B factors and TLS
was performed using default
parameters (final Rwork and Rfree
of 24.9% and 27.2%, respec-
tively). Subsequently, a positional
refinement (with B factors and
TLS) was performed (final Rwork
and Rfree of 21.3% and 27.3%,
respectively). In all cases, clear
density was apparent in the ATP-
binding site. LigandFit (Terwil-
liger et al., 2007) was able to
correctly place the 2-amino-6-(3-
bromophenyl)purine (score of
70.1 and map CC of 0.79). The
structures refined using the
PHENIX and CCP4 suites
showed an r.m.s.d. of 0.21 A˚ on
357 C atoms. In both cases the
orientation of the ligand perfectly
matches that computed using data
at higher resolution (1.5 A˚) and
recorded from a cryocooled
crystal. Similarly, the structures
partially refined using the data at
room temperature showed an
r.m.s.d. from the structure solved
at 100 K of 0.67 A˚ (over 341
common C atoms). In all
cases, the interactions observed
between the ligand and the
protein matched the privileged
interactions in protein kinases.
They included a network of
hydrogen bonds between the 2-
aminopurine edge (through N9,
N3 and N2) and the backbone atoms of the so-called hinge
(residues Leu105–Met106 in Erk-2). In parallel, the purine is
sandwiched by two conserved and hydrophobic residues:
Ala50 and Leu154. The same orientation is observed in CDK2
in complex with a distinct 2-aminopurine compound (Pratt et
al., 2006; PDB entry 2iw9). Additional contacts involved Val37
and the bromophenyl group, which also points towards Gly30
and Gly32 from the glycine-rich loop. Accordingly, this ligand
corresponds to an interesting fragment from which one may
derive better ligands.
The data obtained at room temperature in the crystal-
lization plate compared favourably with the data collected
from a cryocooled crystal. Indeed, the ligand could be readily
recognized after only a few cycles of automatic refinement.
However, in this case the low symmetry coupled with the
limited inclination range of the plate were clearly a drawback
as several crystals were required. Furthermore, the strategy
could not be significantly improved with the current setup as
the crystal orientation could not be changed to improve the
data-set completeness efficiently. This prompted us to further
improve the experiment by allowing larger plate inclinations
of angles of 40/+40 instead of 25/+25. This new
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Table 1
Data-collection and refinement statistics for all complexes described in this study.
Values in parentheses are for the outermost resolution shell.
Protein ligand Erk-2–6PB Erk-2–6PB Erk-2–Z8B Erk-2–Z8B RXR–TBT Native CypD
Data collection Plate Cryoloop Plate Cryoloop Plate Plate
Beamline BM30 ID14-2 BM30 ID14-2 BM30 BM30
Angular range () 50 + 44 + 50 80 50 60 + 17
No. of crystals 3 1 1 1 1 2
Space group P21 P21 P21 P21 P43212 P41212
Unit-cell parameters
a (A˚) 49.1 49.0 49.2 48.7 66.3 57.9
b (A˚) 71.3 70.2 71.1 70.2 66.3 57.9
c (A˚) 60.8 60.1 60.9 59.5 112.2 88.5
 () 109.2 108.7 109.3 108.5
No. of molecules in
asymmetric unit
1 1 1 1 1 1
Wavelength (A˚) 0.97974 0.93300 0.97974 0.93300 0.97974 0.97974
Resolution (A˚) 2.14 1.50 1.93 1.46 2.17 1.54
Rmerge† (%) 4.7 (10.5) 3.8 (17.5) 8.9 (45.2) 3.0 (40.7) 8.9 (46.5) 6.1 (29.9)
hI/(I)i 5.2 (5.7) 11.5 (3.3) 3.7 (1.3) 11.4 (1.0) 6.0 (2.1) 25.7 (4.1)
Completeness (%) 83.1 (80.5) 91.7 (84.2) 70.9 (74.3) 95.1 (73.6) 89.3 (97.6) 86.2 (82.1)
Multiplicity 2.7 (2.8) 1.9 (1.4) 1.8 (1.7) 3.6 (1.9) 2.8 (3.0) 3.6 (2.5)
Wilson B factor (A˚2) 27.6 15.1 31.0 18.1 28.3 17.1
Refinement
Resolution (A˚) 38.90–2.14 36.90–1.50 28.70–1.93 46.18–1.46 57.07–2.17 28.98–1.54
No. of reflections 18304 56567 20223 62682 11386 18518
Rwork‡/Rfree§ (%) 23.1/27.1 13.4/18.4 21.6/27.5 16.1/19.5 23.3/28.3 15.1/19.3
No. of atoms
Protein 2890 2862 2814 2942 1775 1282
Ligand 17 17 24 22 30 —
Water 0 468 224 458 83 126
B factors (A˚2)
Protein} 15.8 16.5 26.8 24.6 30.2 17.1
Ligand 26.3 18.5 42.4 30.5 22.3 —
Water — 35.4 32.4 38.2 34.7 32.4
R.m.s. deviations††
Bond lengths (A˚) 0.009 0.009 0.008 0.008 0.009 0.009

















hkl jFobsj  100. § Rfree is
calculated in the same way as Rwork on a subset of reflections that were not used in the refinement (5%). } B factors for proteins
do not include the anisotropic part simulated by the TLS parameters. †† Deviation from ideal values.
geometry was used for the following
structure of Erk-2 in complex with
another ligand.
3.2. Crystal structure of Erk-2 in
complex with Z8B
As a second test, we used a bromin-
ated adenosine derivative: 8-bromo-
50-azido-50-deoxyadenosine (hereafter
referred to as Z8B). It harbours an
azidoribose, which is a more flexible
substituent compared with that in the
above example. Again, this chemical
compound was known to bind from a
previous experiment using cryocooled
crystals (Fig. 3a; see below).
The new experimental capabilities
were tested in another plate with new
freshly grown Erk-2 crystals subse-
quently soaked with Z8B. Five large
crystals were available for data collec-
tion in the two lanes used in this soaking
assay. Most of them showed poor
diffraction (3 A˚) and appeared to be
polycrystalline. However, one crystal
diffracted very well. Owing to the larger
range (40 to +40) for diffraction
measurements that was made available
on the beamline and the new crystal-
lization plate, a 71% complete data set
was recorded. The crystal again
belonged to the monoclinic space group
P21 and was isomorphous to our
previous Erk-2 crystals. In order to limit
the number of refinement steps and to
avoid too strong a bias, a parallel
molecular replacement was performed
using MOLREP (Vagin & Teplyakov,
2010) through the @TOME-2 server
(Pons & Labesse, 2009). Most structures
of Erk-2 previously deposited in the
PDB (Rose et al., 2011) were tested in
this step (http://atome.cbs.cnrs.fr/AT2/
EG/23295/atome.html). The structure
giving the best solution (according to
the final R and contrast values) was
used in a ten-step rigid-body refinement
in REFMAC5 (Murshudov et al., 1997).
Clear electron density was visible in the
ATP-binding pocket and the adenine
ring could be recognized, while the
bromo group and the ribose appeared
slightly less clearly. Five steps of
restrained refinement were performed
using all data to 1.93 A˚ resolution. The
extra electron density in the ATP-
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Figure 3
In cristallo screening. Crystal structures of an adenosine derivative bound to the Erk-2 active site.
(a) Global structure of Erk-2 bound to 8-bromo-50-amino-50-deoxyadenosine (Z8B) solved at high
resolution and at 100 K. Structure and density are drawn as in Fig. 2. (b) As in Fig. 2(b) but for the
ligand Z8B. (c) As in Fig. 2(c) but for the ligand Z8B. In all panels, the 2Fo  Fc electron-density
map contoured at 0.9 was computed with the ligand molecule omitted from the Fourier synthesis.
This figure was generated using the program PyMOL (http://www.pymol.org).
Figure 2
In cristallo screening. Crystal structures of an adenine derivative bound to the Erk-2 active site. (a)
Global structure of Erk-2 bound to 6-bromophenylpurine solved at high resolution and at 100 K.
The structure is shown as an orange ribbon and the ligand as sticks in CPK colours. (b) Enlargement
of the active site and view of the extra electron density in the active site of Erk-2 observed after
partial refinement using the data set collected at room temperature. The ligand is shown for clarity
but was not included in the refinement (see text). (c) View of the ligand 6-bromophenylpurine and
its electron density in the active site of Erk-2 after final refinement at high resolution using data
recorded at 100 K. In all panels, the 2Fo Fc electron-density map contoured at 0.9 was computed
with the ligand molecule omitted from the Fourier synthesis. The electron density is drawn as a mesh
and a surface in cyan. This figure was generated using the program PyMOL (http://www.pymol.org).
binding cavity indicated that the bromine group was present,
while the azido group was either mobile or labile (see Fig. 3b).
As above, PHENIX (Adams et al., 2010) was used for fully
automatic refinement and the resulting structure highlighted
similar features. Despite the low completeness, the data were
sufficient to indicate ligand binding and its rough orientation
in the ATP-binding site. However, automatic docking into the
density failed as the adenosine was placed in the active site but
in two incorrect orientations (data not shown). The correct
orientation (Fig. 3c) can be determined manually and matched
the usual mode of binding of an adenosine in the active site of
a protein kinase (as shown by Mg-ATP in PDB entry 1gol).
The precise and automatic determination of the ligand con-
formation may require additional measurements or a higher
resolution. The precise structure of the complex was deter-
mined using data recorded at higher resolution from a
cryocooled crystal (Table 1). Compared with the structure in
the complex with 6PB (see above), this new structure shows
some rearrangements in the active site, mainly in the glycine-
rich loop. These changes are necessary to accommodate the
50-derivatization and suggest a way to increase the ligand size
in order to improve its affinity.
This example shows that rapid ligand screening in plates can
be performed even in the case of a low-symmetry space group
(here monoclinic P21 with only one twofold symmetry).
Manual refinement could lead to
a medium-quality structure of the
complex, while automatic and
partial refinement already allows
the recognition of the presence of
a bound adenosine. This could
prompt one to record supple-
mentary data using either addi-
tional crystals present in the plate
or by soaking, mounting and
cryocooling one crystal for
complete data recording.
3.3. Crystal structure of RXR in
complex with an organotin
Using the new plate, we repro-
duced the cocrystallization of the
nuclear receptor RXR in com-
plex with an organotin (tributyl-
tin; hereafter referred to as TBT)
and a co-activator peptide (Tif2).
These crystals allowed us to
collect high-quality data. 50
images were collected from a
single crystal and were used to
solve the structure of the RXR–
TBT–Tif2 complex. This crystal
appeared to be isomorphous to
that previously described (space
group P43212) and diffracted to
beyond 2.0 A˚ resolution. Scaling
of the data provided us with an 89.3% complete data set
(97.6% completeness in the outer resolution shell) at a reso-
lution of 2.17 A˚.
A number of structures of the receptor RXR in its active
form (in complex with an agonist ligand and a coactivator
peptide) have been published and could be used to solve the
new structure. In order to evaluate the potential bias in using a
too closely related structure, two distinct structures were used
as a starting point for the refinement. One template corre-
sponded to the same RXR–TBT–Tif2 complex as that solved
from a cryocooled crystal (PDB entry 3e94; le Maire et al.,
2009) and the second corresponded to a reference structure of
the RXR–9-cis-RA–SRC1 complex (PDB entry 1k74; Xu et
al., 2001). In both cases the small chemical ligands were
omitted during the initial refinement. Firstly, a ten-step rigid-
body refinement using REFMAC5 (Murshudov et al., 1997)
was performed. The resulting R factors were 34 and 40%,
respectively. In both cases, clear density was visible in the
Fo  Fc map and was attributed to an Sn atom. This partial
refinement was already sufficient to identify the ligand and its
binding mode.
Alternatively, as in the case of Erk-2, a semi-automatic
procedure was applied to limit any bias in the refinement.
Molecular replacements using all available RXR structures
were performed in parallel using MOLREP (Vagin &
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Figure 4
In cristallo screening. Crystal structures of RXR complexed with an organotin (TBT). (a) Superposition
of the structure solved from a cryocooled crystal (blue; PDB entry 3e94) with the structure solved from a
crystal at room temperature (orange). (b) OMIT maps of the electron density in the active site of the
structure from a cryocooled crystal (PDB entry 3e94). Fo  Fc (red) and 2Fo  Fc (blue) maps are
contoured at 9.0 and 1.0, respectively. (c) As Fig. 2(b) but for the structure refined from the data
obtained at room temperature in the new plate (see text). This figure was generated using the program
PyMOL (http://www.pymol.org).
Teplyakov, 2010) through the @TOME-2 server (Pons &
Labesse, 2009). The results can be found at http://
atome.cbs.cnrs.fr/AT2/EG/60575/atome.html. Two distinct
structures were used as a starting point for the refinement. The
first template corresponded to the same RXR–TBT–Tif2
complex as previously solved from a cryocooled crystal (PDB
entry 3e94). As expected, the R-factor and contrast values for
this model were the best (43.1% and 8.05, respectively). The
second template corresponded to the structure of RXR in a
binary complex with retinoic acid (PDB entry 1fby; Egea et al.,
2000) and its statistics of molecular replacement were poorer
but acceptable (R factor of 50.3% and contrast of 3.57). In
both models the small chemical ligands were omitted during
the initial refinement. Firstly, a ten-step rigid-body refinement
using REFMAC5 (Murshudov et al., 1997) was performed. The
resulting R factors (Rfree) reached 33.7% (33.7%) and 43.2%
(41.1%) for the models derived from the templates PDB entry
3e94 and PDB entry 1fby, respectively. An additional ten-step
restrained refinement using REFMAC5 diminished the R
factors (Rfree) to 28.5% (33.6%) and 31.6% (37.2%), respec-
tively. In both cases, clear density was visible in the Fo  Fc
map and was attributed to the Sn atom of the ligand (Figs. 4b
and 4c). In addition, the mobile aliphatic chains were also
clearly visible in the 2Fo  Fc map (Fig. 4c).
As in the previously published structure of RXR–TBT (le
Maire et al., 2009), one TBT molecule is bound to two alter-
native conformations of Cys432 (Fig. 4c). Further refinements
using REFMAC5 led smoothly to a very good model of the
complex (Table 1).
In addition, PHENIX (Adams et al., 2010) was also used for
a fully automatic refinement. This procedure also led to the
structure of the complex in a straightforward manner starting
from the same templates (data not shown).
Finally, the structures of the RXR–TBT–Tif2 complex
determined from data collected at room temperature and at
100 K were almost identical (Fig. 4a).
3.4. Crystal structure of unliganded CypD at room
temperature
A new plate was used for setting up crystallization of CypD.
The small number of crystals prevented the testing of ligand
soaking in this case and the crystals were simply tested for
diffraction quality and stability at room temperature under
X-ray irradiation.
A 70% complete data set was readily obtained for CypD
using only one crystal owing to its crystallization in a high-
symmetry space group. A second crystal was used to collect a
dozen additional images in order to increase the completeness
to 86.2% with a multiplicity of 3.6 at a resolution of 1.54 A˚
(Table 1). These crystals were isomorphous to the cryocooled
crystals (Colliandre & Guichou, unpublished work). Again,
parallel molecular replacement was performed (see results
at http://atome.cbs.cnrs.fr/AT2/EG/28727/atome.html). This
structure at room temperature was
solved starting from the structure of
CypD obtained from a cryocooled
crystal (PDB entry 2z6w; Kajitani et al.,
2008). After ten steps of rigid-body
refinement and ten further steps
of restrained refinement in REFMAC5
(Murshudov et al., 1997), a good elec-
tron density appeared. It corresponded
to the apo protein and included all
residues from 44 to 207. Compared with
the starting conformation, several side
chains appeared to be reoriented and
most of them were readily placed into
the electron density using the ‘Auto_
Fit_rotamer’ option in Coot (Emsley &
Cowtan, 2004). The major rearrange-
ment involves only one residue: Gly117.
It is in two alternative conformations in
the template, one of which was selected
in the molecular-replacement step,
while the other would have been closer
to the actual structure at room temp-
erature. To better match the electron
density, the backbone of Gly117 was
translated using the ‘Rotate/Translate
zone’ option and a new round of
restrained refinement was performed. It
showed that Gly117 forms a hydrogen
bond through its N atom to the side
research papers
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Figure 5
Crystal structures of cyclophilin CypD. (a) Superposition of the structure at room temperature of
the unbound protein (PDB entry 3qyu; orange ribbon) with the equivalent structure at 120 K (PDB
entry 2bit; magenta ribbon) and the structure bound to cyclosporin A (PDB entry 2r6w; blue
ribbon). (b) Views of the 2Fo  Fc electron-density map in the region of Gly117 (residues 115–119).
The map is contoured at 0.9. (c) Views of the 2Fo  Fc electron-density map in the active site for a
set of hydrophobic residues lying in the active site (Met102, Phe103, Phe155, Trp163 and Leu164).
The map is contoured at 0.9. This figure was generated using the program PyMOL (http://
www.pymol.org).
chain of Thr110 (N—O1 distance of2.85 A˚). A concomitant
repositioning of the side chain of Arg124 allows another
hydrogen bond to the carbonyl of Gly117 (O—N1 distance of
2.98 A˚).
In addition, as a final round of rebuilding, several alter-
nating side chains were built and some water molecules were
added using Coot. This quick and semi-automatic rebuilding
followed by restrained refinement using anisotropic B factors
led to an optimal model with very good parameters (R factor
and Rfree of 15.1% and 19.3%, respectively; Table 1). Only
minor changes were observed (Fig. 5a) between the template
and the final structure solved at room temperature (r.m.s.d. of
0.29 A˚ over 164 C atoms). The latter slightly converged to the
structure of the unbound CypD previously solved at 120 K
(PDB entry 2bit; Schlatter et al., 2005), showing an r.m.s.d. of
0.18 A˚. All this may be a consequence of the fact that the
template used for molecular replacement corresponds to the
enzyme bound to its nanomolar inhibitor cyclosporin A
(Kajitani et al., 2008). This example shows that in situ
measurement can yield excellent data at high resolution (see
details of the electron density in Figs. 5b and 5c). Attempts to
reproduce these crystals and soak them with ligands of interest
will be made in the near future.
4. Discussion
In this study, we have successfully evaluated the use of new
plates for crystal growth, for ligand soaking and finally for
direct X-ray measurements without removing the crystals
from the plate. This method takes advantage of the enhanced
capabilities of the G-Rob robot for plate handling during data
collection.
In the case of the protein kinase Erk-2, which crystallizes in
a monoclinic space group, soaking and ligand detection were
successfully performed for two distinct chemical compounds.
Firstly, a data set was obtained at 83% completeness using
three distinct crystals soaked with a purine derivative. Further
optimization in the angle range accessible to the plate in the
X-ray beam (from25 to + 25 to40 to + 40) led to a 71%
complete data set for the same protein using only one crystal.
In both cases the ligands were clearly visible in the OMIT
map.
For the nuclear receptor studied, which crystallizes in a
high-symmetry space group, a complete data set was collected
at 2.17 A˚ resolution. The deduced structure at room temp-
erature perfectly matches that previously computed using
diffraction from an equivalent but cryocooled crystal (le Maire
et al., 2009). In addition, comparisons of the statistics suggest
that the main limit arises from the accessible multiplicity.
Finally, a high-resolution data set (1.54 A˚) was obtained for
another protein, human mitochondrial cyclophilin CypD.
Although it was performed in the absence of added ligand, the
atomic resolution (1.54 A˚) and the quality of the resulting
electron density indicate that ligands would readily be
recognized upon binding. Data recorded on the same
synchrotron beamline using a crystal mounted in a cryoloop
(in the presence of an inhibitor; Colliandre & Guichou, to be
published elsewhere), diffracting to the same resolution limit,
showed very similar statistics (including Rmerge, R factor etc.).
While our first interest was to check the capacity of the
setup to provide information on the mode of binding of
potential ligands, alternative applications can also be envis-
aged. First of all, soaking with heavy-atom derivatives is
promising. Secondly, the impact of additives on the diffraction
quality can be tested rapidly. This will require further
evaluation as well as the setting up of highly reproducible
conditions for crystal growth. This step will remain a challenge
for the use of the technique described here, although recent
developments such as microseeding beads represent a
promising tool, as exemplified with the proteins Erk-2 and
CypD.
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